Condition
Endometrial Adenocarcinoma
ClinicalTrials.gov condition label
How to interpret these research links
Connected source recordsThis is the original ClinicalTrials.gov condition label, found in 7 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.
Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.
Advertisement
Clinical trials
7 shownDBC-664 in Adult Patients With Solid TumorsNCT07705035 · 2026-07-17
RECRUITINGClonal Hematopoiesis Chemotherapy and Radiation Effects StudyNCT07675967 · 2025-04-04
RECRUITINGA Study to Investigate APL-5125 in Adults With Advanced Solid TumorsNCT06399757 · 2024-06-18
COMPLETEDAMT-151 in Patients With Selected Advanced Solid TumoursNCT05498597 · 2023-01-25
UNKNOWNPEN-866 in Patients With Advanced Solid MalignanciesNCT03221400 · 2017-08-29
UNKNOWNPembro/Carbo/Taxol in Endometrial CancerNCT02549209 · 2017-08-22
COMPLETEDmTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial and OvarianNCT02208375 · 2014-11-11
ACTIVE_NOT_RECRUITINGCommon interventions
Leading sponsors
Trial status mix
COMPLETED2
RECRUITING2
UNKNOWN2
ACTIVE_NOT_RECRUITING1
Phase mix
PHASE15
PHASE22
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.